Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;28(2):313-20.
doi: 10.1007/s11011-013-9392-4. Epub 2013 Mar 2.

Disaccharides in the Treatment of Hepatic Encephalopathy

Affiliations
Review

Disaccharides in the Treatment of Hepatic Encephalopathy

Praveen Sharma et al. Metab Brain Dis. .

Abstract

Management of hepatic encephalopathy (HE) primarily involves avoidance of precipitating factors and administration of various ammonia-lowering therapies such as nonabsorbable disaccharides and antimicrobial agents like rifaximin. The nonabsorbable disaccharides which include lactulose and lactitol are considered the first-line therapy for the treatment of HE and minimal hepatic encephalopathy (MHE). Lactulose significantly improves cognitive function and health-related quality of life in patients with MHE. Lactitol is comparable to lactulose in the treatment of HE with fewer side effects. Lactulose has also shown to be effective in primary and secondary prophylaxis of HE. Disaccharides were found to be comparable to rifaximin in recent systemic reviews in the treatment of HE however conclusion was based on inclusion of some poor quality trials. Combination therapy of disaccharides either with rifaximin, L-ornithine L-aspartate,probiotics for the treatment of HE needs further validation in large studies.

Similar articles

See all similar articles

Cited by 9 articles

See all "Cited by" articles

References

    1. Am J Gastroenterol. 2001 Sep;96(9):2718-23 - PubMed
    1. Saudi J Gastroenterol. 2011 Mar-Apr;17(2):138-41 - PubMed
    1. Gastroenterology. 1970 Dec;59(6):827-32 - PubMed
    1. Cochrane Database Syst Rev. 2011 Nov 09;(11):CD008716 - PubMed
    1. J Hepatol. 2003 Jan;38(1):51-8 - PubMed

MeSH terms

LinkOut - more resources

Feedback